Arthur C. Louie

Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy.

G. Fyfe, Richard I. Fisher, S A Rosenberg et al. · Journal of Clinical Oncology · 1995 · 1.4K citations

Medicine, Oncology, Pharmacology +16

CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia

Jeffrey E. Lancet, Geoffrey L. Uy, Jörge E. Cortes et al. · Journal of Clinical Oncology · 2018 · 990 citations · Full text

Medicine, Oncology, Pharmacology +15

Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML

Jeffrey E. Lancet, Jörge E. Cortes, Donna E. Hogge et al. · Blood · 2014 · 336 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +6

First-In-Man Study of CPX-351: A Liposomal Carrier Containing Cytarabine and Daunorubicin in a Fixed 5:1 Molar Ratio for the Treatment of Relapsed and Refractory Acute Myeloid Leukemia

Eric J. Feldman, Jeffrey E. Lancet, Jonathan E. Kolitz et al. · Journal of Clinical Oncology · 2011 · 300 citations · Full text

Medicine, Clinical Pharmacokinetics, Pharmacology +17

Randomized phase II trial of high-dose interleukin-2 either alone or in combination with interferon alfa-2b in advanced renal cell carcinoma.

Michael B. Atkins, Joseph A. Sparano, Richard I. Fisher et al. · Journal of Clinical Oncology · 1993 · 219 citations

Medicine, Oncology, Pharmacotherapy +17